noom glp 1 Med Plans & Pricing Noom GLP-1 Access and Transparency
Description
The mean percentage of body weight loss at 72 weeks was 15.0% at the lowest dose, and 20.9% in the highest dose cohort (compared to 3.1% in placebo) (NCT04184622)
Platform Analysis
What did they find
I expect other weight loss medications using the GLP-1 agonist mechanism of action, or GLP-1 in combination with other drugs, to come through the pipeline soon.
Further studies revealed that (Ex-4)2-Fc inhibits NF-B and p38 phosphorylation in adipose tissue while suppressing the MAPK signaling pathway
